{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:36:01Z","timestamp":1778661361411,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.imbio.2020.151982","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T11:15:03Z","timestamp":1594034103000},"page":"151982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of a peptide targeting CD56"],"prefix":"10.1016","volume":"225","author":[{"given":"Hongxing","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoming","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2020.151982_bib0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.imbio.2020.151982_bib0010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00262-016-1792-y","article-title":"Selection and expansion of natural killer cells for NK cell-based immunotherapy","volume":"65","author":"Becker","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imbio.2020.151982_bib0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2741\/4202","article-title":"Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma","volume":"19","author":"Berdeja","year":"2014","journal-title":"Front. Biosci. Landmark (Landmark Ed)"},{"key":"10.1016\/j.imbio.2020.151982_bib0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/35095564","article-title":"Natural killer cells, viruses and cancer","volume":"1","author":"Cerwenka","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imbio.2020.151982_bib0025","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1039\/C7OB01092C","article-title":"Self-assembly of bioactive peptides, peptide conjugates, and peptide mimetic materials","volume":"15","author":"Edwards-Gayle","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.imbio.2020.151982_bib0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/cr400166n","article-title":"Combinatorial peptide libraries: mining for cell-binding peptides","volume":"114","author":"Gray","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.imbio.2020.151982_bib0035","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1590\/abd1806-4841.20187097","article-title":"Nasal-type extranodal T-cell\/NK lymphoma in association with hemophagocytic syndrome","volume":"93","author":"Guedes","year":"2018","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.imbio.2020.151982_bib0040","doi-asserted-by":"crossref","first-page":"14015","DOI":"10.1021\/acs.chemrev.7b00522","article-title":"Small bioactive peptides for biomaterials design and therapeutics","volume":"117","author":"Hamley","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.imbio.2020.151982_bib0045","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.imbio.2020.151982_bib0050","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jcyt.2014.09.007","article-title":"Challenges of cancer therapy with natural killer cells","volume":"17","author":"Klingemann","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.imbio.2020.151982_bib0055","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3389\/fonc.2013.00118","article-title":"Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol","volume":"3","author":"Koehl","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imbio.2020.151982_bib0060","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.imbio.2020.151982_bib0065","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1096\/fj.05-4058com","article-title":"Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.imbio.2020.151982_bib0070","first-page":"2935","article-title":"A novel peptide targets CD105 for tumour imaging in vivo","volume":"40","author":"Li","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.imbio.2020.151982_bib0075","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.4049\/jimmunol.1502570","article-title":"Human CD56bright NK cells: an update","volume":"196","author":"Michel","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.imbio.2020.151982_bib0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cyto.990110203","article-title":"High gradient magnetic cell separation with MACS","volume":"11","author":"Miltenyi","year":"1990","journal-title":"Cytometry"},{"key":"10.1016\/j.imbio.2020.151982_bib0085","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/15321819.2014.952444","article-title":"CD56 antibody: old-fashioned or still trendy in endocrine lung tumors","volume":"36","author":"Mlika","year":"2015","journal-title":"J. Immunoassay Immunochem."},{"key":"10.1016\/j.imbio.2020.151982_bib0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163648","article-title":"Identification and tumour-binding properties of a peptide with high affinity to the disialoganglioside GD2","volume":"11","author":"M\u00fcller","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.imbio.2020.151982_bib0095","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1016\/j.chroma.2010.07.048","article-title":"Chromatographic biopanning for the selection of peptides with high specificity to Pb2+ from phage displayed peptide library","volume":"1217","author":"Nian","year":"2010","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.imbio.2020.151982_bib0100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.imbio.2020.151982_bib0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/jb\/mvm109","article-title":"Identification of a novel peptide ligand of human vascular endothelia growth factor receptor 3 for targeted tumour diagnosis and therapy","volume":"142","author":"Qin","year":"2007","journal-title":"J. Biochem."},{"key":"10.1016\/j.imbio.2020.151982_bib0110","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2016.11.060","article-title":"Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship","volume":"482","author":"Sakamoto","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.imbio.2020.151982_bib0115","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10637-016-0336-9","article-title":"Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors","volume":"34","author":"Shah","year":"2016","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.imbio.2020.151982_bib0120","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.1158\/0008-5472.CAN-05-0188","article-title":"A novel peptide specifically binding to interleukin-6 receptor (gp80) inhibits angiogenesis and tumor growth","volume":"65","author":"Su","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.imbio.2020.151982_bib0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00795-014-0072-1","article-title":"CD56-positive adult T-cell leukemia\/lymphoma: a case report and a review of the literature","volume":"48","author":"Sugimoto","year":"2015","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.imbio.2020.151982_bib0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1359-6446(05)03638-X","article-title":"Elimination mechanisms of therapeutic monoclonal antibodies","volume":"11","author":"Tabrizi","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.imbio.2020.151982_bib0135","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.humpath.2003.09.015","article-title":"Clinicopathologic differences between 22 cases of CD56-negative and CD56-positive subcutaneous panniculitis-like lymphoma in Japan","volume":"35","author":"Takeshita","year":"2004","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.imbio.2020.151982_bib0140","article-title":"Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library","volume":"8","author":"Tang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.imbio.2020.151982_bib0145","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/17474086.2016.1206465","article-title":"Diagnosis and management of extranodal NK\/T cell lymphoma nasal type","volume":"9","author":"Tse","year":"2016","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.imbio.2020.151982_bib0150","doi-asserted-by":"crossref","first-page":"556","DOI":"10.4161\/mabs.27756","article-title":"Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models","volume":"6","author":"Whiteman","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.imbio.2020.151982_bib0155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.intimp.2018.09.042","article-title":"A new ligand of CD105 screened out by phage display technology provides a reliable identification of recurrent or metastasizing pleomorphic adenoma from pleomorphic adenoma","volume":"65","author":"Yu","year":"2018","journal-title":"Int. Immunopharmacol."}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298520300978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298520300978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:47:41Z","timestamp":1759250861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298520300978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0171298520300978"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2020.151982","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of a peptide targeting CD56","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2020.151982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151982"}}